Liraglutide augments weight loss in pre-type 2 diabetes

Liraglutide augments weight loss in pre-type 2 diabetes
For patients at high risk of type 2 diabetes mellitus and cardiovascular disease, liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin resistance, glucose tolerance, and some cardiovascular disease risk factors, according to a study published online July 8 in Diabetes Care.

(HealthDay)—For patients at high risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin resistance, glucose tolerance, and some CVD risk factors, according to a study published online July 8 in Diabetes Care.

Sun H. Kim, M.D., from the Stanford University School of Medicine in California, and colleagues randomized 68 older individuals (mean age, 58 years) with overweight/obesity and prediabetes to receive liraglutide (35 patients) or placebo (33 patients) for 14 weeks. Participants were advised to lower calorie intake by 500 kcal/day. Measurement of the steady-state (SSPG) concentration during the insulin suppression test was used to quantify peripheral ; inflammatory markers and traditional CVD risk factors were also evaluated.

Eleven individuals assigned to liraglutide and six assigned to placebo discontinued the study. The researchers found that weight loss was significantly higher for those who continued to use liraglutide (6.8 kg) versus placebo (3.3 kg). There were also significant improvements in SSPG concentration and significantly greater lowering of systolic blood pressure, fasting glucose, and triglyceride concentration among liraglutide-treated subjects. Pulse increased significantly after liraglutide treatment, but inflammatory markers were similar in the two groups.

"The addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for development of T2DM and CVD," the authors write.

Liraglutide and matching placebo were provided by Novo Nordisk.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Genetic risk score linked to increased risk of diabetes

Jul 30, 2013

(HealthDay)—A genetic risk score based on 46 gene variants linked to type 2 diabetes is associated with increases in the risk of type 2 diabetes and declines in glucose control and beta-cell function, according ...

Recommended for you

Economic burden of prediabetes up 74 percent over five years

Nov 20, 2014

The economic burden of diabetes in America continues to climb, exceeding more than $322 billion in excess medical costs and lost productivity in 2012, or more than $1,000 for every American, according to a study being published ...

Gynoid fat resists metabolic risks of obesity

Nov 19, 2014

(HealthDay)—The differences in the developmental profiles of upper-body and lower-body fat depots may explain their opposing associations with obesity-related metabolic disease, according to research published ...

Treating diabetes one meal at a time

Nov 19, 2014

Recent estimates project that as many as one in three American adults will have diabetes in 2050. The American Diabetes Association observes November as American Diabetes Month, and this year's theme is America ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

purasilk
not rated yet Aug 15, 2013
The best way to lose weight fast is http://tinyurl.com/onljzp6

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.